Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats. (Q34318349)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats.	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Selective SGLT2 inhibition by tofogliflozin reduces renal glucose reabsorption under hyperglycemic but not under hypo- or euglycemic conditions in rats (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

based on heuristic

inferred from title

13

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Takumi Nagata

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Masanori Fukazawa

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Kiyofumi Honda

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Tatsuo Yata

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mio Kawai

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Mizuki Yamane

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Naoaki Murao

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Koji Yamaguchi

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Motohiro Kato

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Tetsuya Mitsui

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Yoshiyuki Suzuki

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sachiya Ikeda

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

publication date

18 December 2012

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

American Journal of Physiology - Endocrinology and Metabolism

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

304

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

E414-23

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23249697%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Functional characterization of mouse sodium/glucose transporter type 3b

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Effect of 5-aminoimidazole-4-carboxamide-1-beta-D-ribofuranoside infusion on in vivo glucose and lipid metabolism in lean and obese Zucker rats.

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

SGLT2 inhibition--a novel strategy for diabetes treatment

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

THE ACTION OF PHLORIZIN ON THE EXCRETION OF GLUCOSE, XYLOSE, SUCROSE, CREATININE AND UREA BY MAN.

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects.

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Development and testing of a simple algorithm for a glucose clamp.

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Glucose transport by human renal Na+/D-glucose cotransporters SGLT1 and SGLT2.

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Comment on: Vila et al. B-type natriuretic peptide modulates ghrelin, hunger, and satiety in healthy men. Diabetes 2012;61:2592-2596.

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Sergliflozin, a novel selective inhibitor of low-affinity sodium glucose cotransporter (SGLT2), validates the critical role of SGLT2 in renal glucose reabsorption and modulates plasma glucose level

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Dapagliflozin, a novel SGLT2 inhibitor, induces dose-dependent glucosuria in healthy subjects

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

A novel SGLT is expressed in the human kidney

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Why Do SGLT2 inhibitors inhibit only 30-50% of renal glucose reabsorption in humans?

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Discovery of tofogliflozin, a novel C-arylglucoside with an O-spiroketal ring system, as a highly selective sodium glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo.

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

The proximal tubule in the pathophysiology of the diabetic kidney

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

SGLT2 mediates glucose reabsorption in the early proximal tubule.

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Biology of human sodium glucose transporters

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Pharmacokinetic and pharmacodynamic modeling of the effect of an sodium-glucose cotransporter inhibitor, phlorizin, on renal glucose transport in rats

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.00545.2012

21 January 2018

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34318349&oldid=1180002806"